MAM
Perfetti Van Melle India appoints Rajesh Ramakrishnan as MD
MUMBAI: Leading confectionery player Pertfetti Van Melle India has recently appointed Rajesh Ramakrishnan as the new MD of the company. Ramakrishnan will replace Ramesh Jayaraman who has moved to another role within the group.
In his new role he will be responsible for the operations of the company for India and Nepal.
Ramakrishnan joined Perfetti Van Melle in 2014 as a managing director for Bangladesh. Under his leadership, Perfetti Van Melle, Bangladesh delivered sustained growth and achieved market leadership in 2016. In August 2017, Rajesh moved to India as the chief transformation officer. As the CTO, he worked with the business teams in strategising and delivering the key elements of the business transformation project to drive topline and bottomline growth.
Perfetti Van Melle president Huub Sanders said, “Rajesh is an accomplished leader, who brings in a good mix of strategic thinking and operational excellence, with strong leadership skills. We are delighted to have him as our India head and wish him all the very best in his new role.”
Ramakrishnan brings with him 24 years of experience in diverse fields like sales, marketing and general management in Asia across the categories such has personal care, household care, foods and beverages, confectionery and media. Rajesh is a graduate of XLRI Jamshedpur and BITS Pilani.
Prior to joining Perfetti Van Melle, Ramakrishnan was the marketing head at HT Media Ltd. In India, he has also worked in various sales and marketing roles for Pepsico, Marico Industries and Reckitt Benckiser.
Rajesh is an award winning photographer. His work has been featured at Cannes and has also been published in several publications in India and outside.
Brands
Bayer sues Johnson & Johnson over prostate cancer drug advertisements
Legal dispute begins as Bayer claims rival marketing is based on flawed data
NEW YORK: Bayer has filed a federal lawsuit against Johnson & Johnson (J&J) in New York, alleging that the American pharmaceutical company has used false and misleading advertisements to promote its prostate cancer treatment, Erleada. The dispute centres on claims that Erleada is significantly more effective than Bayer’s competing drug, Nubeqa.
The legal action follows a J&J marketing campaign that cited a 51 per cent reduction in the risk of death for patients using Erleada compared to those on Nubeqa. Bayer contends that these figures are based on a study with severe methodological errors rather than a controlled clinical trial.
Bayer’s legal team argues that J&J’s real-world analysis is fundamentally flawed. According to the complaint, J&J claimed to have 24 months of patient data supporting its conclusions, even though many patients included in the study had reportedly been on the medication for only a few months, raising concerns about the reliability of long-term survival comparisons.
The lawsuit also highlights what Bayer describes as a critical approval gap. For most of the period analysed in J&J’s study, Nubeqa had not yet been approved for the specific indication being evaluated, which Bayer argues makes a direct clinical comparison inappropriate and potentially misleading.
Additionally, Bayer contends that the study suffered from significant sample imbalance. The analysis reportedly included five times as many Erleada patients as Nubeqa patients, a disparity that Bayer says introduced statistical bias and undermined the validity of the findings.
Bayer is pursuing the case under the Lanham Act, the U.S. law governing false advertising and unfair competition. The company is seeking an immediate halt to J&J’s current marketing campaign and is asking the court to require corrective statements to physicians to address what it characterises as inaccurate claims.
Furthermore, Bayer is seeking monetary damages, arguing that the alleged misleading advertisements have resulted in lost revenue and reputational harm to Nubeqa.
Johnson & Johnson has responded by stating that it stands by the integrity of its data and the rigour of its analysis. The case will now proceed through the U.S. District Court for the Southern District of New York.
